Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis: Experience from 92 Sites in an Open-Label US Expanded Access Program

INTRODUCTION: In phase 3 clinical trials, pirfenidone significantly slowed disease progression with a well-defined and medically manageable safety profile in patients with idiopathic pulmonary fibrosis (IPF). This study examined safety events related to pirfenidone in patients with IPF in an expande...

Descripción completa

Detalles Bibliográficos
Autores principales: Lancaster, Lisa, Morrison, Lake, Auais, Alexander, Ding, Beiying, Iqbal, Ahmar, Polman, Boris, Flaherty, Kevin R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964201/
https://www.ncbi.nlm.nih.gov/pubmed/32026347
http://dx.doi.org/10.1007/s41030-017-0049-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964201/
https://www.ncbi.nlm.nih.gov/pubmed/32026347
http://dx.doi.org/10.1007/s41030-017-0049-z

Ejemplares similares